Benatar et al. outline key recommendations from a multi-stakeholder workshop aimed at building consensus across the ALS and FTD communities on the design of a prevention trial for people at elevated genetic risk of C9orf72-associated disease. This evidence concerns the gene C9orf72 and frontotemporal dementia.